Bayer Completes Transaction Involving Plasma Business

Bayer confirmed it has completed its previously announced transaction to contribute the assets of its worldwide plasma products business to Talecris Biotherapeutics, a newly formed corporation controlled by affiliates of Cerberus Capital Management, New York, and Ampersand Ventures, Wellesley, Mass. The overall transaction volume amounts to approximately $590 million, including cash, a 10 percent equity interest in Talecris Biotherapeutics Holdings, retention of selected working capital items and contingent payments of up to $60 million.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050401005262&newsLang=en%20)